AI Article Synopsis
- Antisynthetase syndrome is a serious disorder related to dermatomyositis/polymyositis, associated with significant health risks.
- A 71-year-old man diagnosed with this syndrome was treated with rituximab, but nearly three years later, he experienced severe neurological decline, including hemiparesis and cognitive deterioration.
- The patient's condition was ultimately linked to progressive multifocal leukoencephalopathy, and the rituximab treatment contributed to the risk of these complications.
Article Abstract
Antisynthetase syndrome is a disorder belonging to the dermatomyositis/polymyositis group, with high rates of morbidity and mortality. We herein present the case of a 71-year-old man who was diagnosed with antisynthetase syndrome and treated with rituximab. Almost three years later, the patient showed right-sided hemiparesis that ultimately progressed to complete hemiplegia and advancing cognitive deterioration with a poor clinical outcome. The neuropathological diagnosis was progressive multifocal leukoencephalopathy. Treatment with rituximab for antisynthetase syndrome itself plays a fundamental role in the development of infectious complications.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2169/internalmedicine.54.2748 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The advent of chimeric antigen receptor T Cell therapy in recalibrating immune balance for rheumatic autoimmune disease treatment.
Front Pharmacol
December 2024
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
CAR-T cell therapy, a cutting-edge cellular immunotherapy with demonstrated efficacy in treating hematologic malignancies, also exhibits significant promise for addressing autoimmune diseases. This innovative therapeutic approach holds promise for achieving long-term remission in autoimmune diseases, potentially offering significant benefits to affected patients. Current targets under investigation for the treatment of these conditions include CD19, CD20, and BCMA, among others.
View Article and Find Full Text PDF[Analysis of clinical features of ruccrent interstitial lung disease in patients with anti-EJ positive antisynthetase syndrome].
Beijing Da Xue Xue Bao Yi Xue Ban
December 2024
Department of Rheumatology and Immunology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Objective: To summarize the clinical characteristics of 57 patients diagnosed with anti-glycyl tRNA synthetase (anti-EJ) positive antisynthetase syndrome (ASS), a subtype of anti-glycyl tRNA positive ASS, complicated by interstitial lung disease (ILD), and to investigate the factors asso-ciated with ILD recurrence.
Methods: A retrospective analysis was conducted on the clinical data of 57 anti-EJ positive ASS patientswho were treated at the First Affiliated Hospital of Nanjing Medical University from January 1, 2020 to June 30, 2024. The data collected included demographic information, clinical characteristics, laboratory test results, chest CT findings, and pulmonary function tests.
[Immunological characteristics of patients with anti-synthetase syndrome overlap with rheumatoid arthritis].
Beijing Da Xue Xue Bao Yi Xue Ban
December 2024
Department of Rheumatology and Immunology, Peking University People' s Hospital, Beijing 100044, China.
Article Synopsis
- - The study aimed to examine the clinical and immune system characteristics of patients with anti-synthetase syndrome (ASS) who also have rheumatoid arthritis (RA) compared to those without RA.
- - Out of 104 ASS patients with arthritis, 23.1% were diagnosed with RA and displayed notable differences such as higher rates of rapidly progressive interstitial lung disease, more tender and swollen joints, and increased bone erosion compared to the non-RA group.
- - The overlap group (ASS with RA) also had significantly altered immune cell profiles, including decreased regulatory T cells and B cells, as well as higher levels of certain inflammatory markers, leading to a lower rate of complete clinical response.
A Rare and Relentless Foe: Antisynthetase Syndrome Presenting as Refractory Interstitial Lung Disease in a Young Girl.
Pediatr Pulmonol
December 2024
Department of Pediatrics, All India Institute of Medical Sciences Jodhpur, Jodhpur, Rajasthan, India.
Idiopathic inflammatory myopathies related lung disease in adults.
Lancet Respir Med
November 2024
Department of Pulmonary and Critical Care Medicine, Integrated Hospital Care Institute, Cleveland Clinic, Cleveland, OH, USA.
Article Synopsis
- Interstitial lung disease (ILD) frequently occurs in adults with idiopathic inflammatory myopathies, particularly those with antisynthetase syndrome and anti-MDA5 antibodies, manifesting in various severities from mild to rapidly worsening symptoms.
- Common symptoms include lung issues along with myositis, skin lesions, arthritis, and Raynaud’s phenomenon, but 16-65% may have lung problems as the only indication.
- Treatment typically involves immunosuppression, combining therapies for aggressive cases, and possibly lung transplantation for severe cases, although short-term mortality is notably high in rapidly progressive disease associated with anti-MDA5 antibodies.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!